PUT - SPRINTER OPEN END - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 10:43:41 2024-05-20 EDT | ||
| 3.64 EUR | +0.55% |
|
| Current month | -0.55% | ||
| 1 month | +9.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 3.64 | +0.55% |
| 24-05-17 | 3.62 | -0.28% |
| 24-05-16 | 3.63 | +1.68% |
| 24-05-15 | 3.57 | -0.56% |
| 24-05-14 | 3.59 | +0.84% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 10:43 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VX9XBR |
| ISIN | DE000VX9XBR0 |
| Date issued | 2022-04-07 |
| Strike | 83.48 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.71 € |
|---|---|
| Lowest since issue | 0.41 € |
| Spread | 0.01 € |
| Spread % | 0.27% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
44.03
USD
Average target price
53.19
USD
Spread / Average Target
+20.81%
- Stock Market
- Certificates
- Certificat
